



# HOKKAIDO UNIVERSITY

Title	Impact of RNF213 founder polymorphism (p.R4810K) on the postoperative development of indirect pial synangiosis after direct/indirect combined revascularization surgery for adult Moyamoya disease
Author(s)	Ito, Masaki; Kawabori, Masahito; Sugiyama, Taku et al.
Citation	Neurosurgical review, 45(3), 2305-2313 <a href="https://doi.org/10.1007/s10143-022-01749-9">https://doi.org/10.1007/s10143-022-01749-9</a>
Issue Date	2022-06
Doc URL	<a href="https://hdl.handle.net/2115/89787">https://hdl.handle.net/2115/89787</a>
Rights	This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature's AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: <a href="http://dx.doi.org/10.1007/s10143-022-01749-9">http://dx.doi.org/10.1007/s10143-022-01749-9</a>
Type	journal article
File Information	Neurosurg Rev s10143-022-01749-9.pdf



Impact of *RNF213* founder polymorphism (p.R4810K) on the postoperative development of indirect pial synangiosis after direct/indirect combined revascularization surgery for adult Moyamoya disease

Masaki Ito, Masahito Kawabori, Taku Sugiyama, Kikutaro Tokairin, Ryota Tatezawa, Haruto Uchino, Ken Kazumata, Kiyohiro Houkin, Miki Fujimura

Department of Neurosurgery, Hokkaido University Graduate School of Medicine, Sapporo, 060-8638, Japan

**Corresponding Author:** Masaki Ito, M.D., Ph.D.

Department of Neurosurgery, Hokkaido University Graduate School of Medicine, North 14, West 5, Sapporo 060-8648, Japan

Tel: +81-11-706-5987, FAX: +81-11-708-7737, E-mail: [masakiitou-nsu@umin.ac.jp](mailto:masakiitou-nsu@umin.ac.jp)

ORCID: 0000-0002-8032-7198

## **Abstract**

Direct superficial temporal artery (STA) to middle cerebral artery (MCA) anastomosis combined with indirect pial synangi- osis provides favorable surgical collaterals for Moyamoya disease (MMD), especially in adults; however, factors leading to the development of each direct and indirect collateral are not well documented.

We aimed to investigate the association between RNF213 founder polymorphism (p.R4810K) and each direct and indirect collateral development. By qualitative and quantitative evaluations of direct and indirect surgical collaterals using time-of- flight MR angiography, postoperative development of each type of bypass was evaluated independently into two categories. Multivariate logistic regression analysis was performed to study the contributing factors for the development of each surgical collateral.

Excellent development of postoperative direct and indirect bypass was observed in 65 hemispheres (70%) by qualitative evaluation, which was confirmed by quantitative evaluation. Multivariate logistic regression analysis of excellent indirect bypass development revealed a significant positive correlation with the p.R4810K (odds ratio, OR4.0; 95%-confidence interval, CI 1.2–16), advanced MR angiographic stage (OR9.5; 95%CI 1.7–73), and preoperative middle meningeal artery caliber (OR6.8; 95%CI 1.8–35), but a significant negative correlation was found with the excellent direct bypass development (OR0.17; 95%CI 0.03–0.75). No significant correlation was observed between excellent direct bypass development and the p.R4810K (OR0.95; 95%CI 0.37–2.4).

In conclusion, excellent development of indirect collaterals after STA-MCA anastomosis combined with indirect pial synan- giosis occurs more frequently in adult MMD with the RNF213 founder polymorphism, suggesting a role of the p.R4810K variant for marked in-growth of indirect collaterals and the utility of preoperative genetic analysis.

**Key Words:** Moyamoya; Magnetic resonance imaging; Polymorphism, Revascularization; RNF213; Vascular disorders

## **Declarations**

**Funding:** This study was partially supported by Japanese Society for the Promotion of Science KAKENHI grant number 19H03765 (M.I.) and 20K09362 (M.F.). All authors declare that there is no personal or institutional financial interest in drugs, materials, or devices described in this article.

**Conflicts of interest/Competing interests:** On behalf of all authors, the corresponding author state that the authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

**Availability of data and material:** Data supporting the findings of this study are available from the corresponding author on reasonable request.

**Code availability:** Not applicable

**Authors' contributions:** Conception and design: Fujimura M, Ito M, and Kawabori M. Acquisition of data: Ito M., Sugiyama T, Tokairin K, Tatzawa R. Analysis and interpretation of data: Ito M, Kawabori M, Sugiyama T, Tokairin K, Tatzawa R, Uchino H, and Fujimura M. Drafting the article: Ito M. Critically revising the article: Kazumata K, and Fujimura M. Statistical analysis: Ito M. Study supervision: Kazumata K and Houkin K.

**Ethics approval:** The present study was approved by the Hokkaido University Graduate School of Medicine medical ethics committee on human experimentation, including genetic analysis (14-053).

**Consent to participate:** Written informed consent was obtained from all participants (or guardians) to participate in this study.

**Consent to publication:** Written informed consent was obtained from all participants (or guardians) whose individual data were presented for publication in this study in any form.

### **Acknowledgements**

We would like to acknowledge Ms. Rika Nagashima and Ms. Ikuyo Hata for their administrative assistance. We also thank Dr. Hiroyuki Kohno, Dr Kanako Hatanaka, and Ms. Miyuki Kasegai for their technical support in the genetic analysis.

## 1 Introduction

2 Moyamoya disease (MMD) is characterized by progressive stenosis of the terminal  
3 portion of the internal carotid arteries, accompanied by the formation of abnormally  
4 dilated, fragile perforators at the base of the brain. [18, 31, 33] Direct superficial  
5 temporal artery (STA) to middle cerebral artery (MCA) anastomosis is accepted  
6 worldwide as the primary treatment of choice aiming at improving cerebral blood flow  
7 and surgical revascularization for symptomatic ischemic and hemorrhagic presentations  
8 of MMD. [17, 26] While direct STA-MCA anastomosis offers the advantage of  
9 immediate revascularization, indirect bypass effectively induces the in-growth of new  
10 collaterals to the underlying cerebral cortex overtime. [18, 31] In the combined setting  
11 using both direct and indirect bypass, the advantages of both bypass procedures are  
12 expected, with a perioperative stroke risk of 4.7% per surgery but a favorable long term  
13 clinical outcome. [15, 20] Several studies demonstrated a reciprocal relationship  
14 between the direct and indirect bypass with a wider extent of surgical revascularization  
15 in the context of a combined setting. [1, 2, 36, 37] Very recently, the association  
16 between a *RNF213* founder mutation for east Asian MMD (p.R4810K) [14, 23] and  
17 postoperative development of surgical collaterals has been demonstrated,[8] however, it  
18 is still obscure for which type of surgical collateral (i.e., direct or indirect or both?) the  
19 *RNF213* founder mutation is responsible.

20 The extent of revascularization after Moyamoya bypass surgery is  
21 traditionally examined by catheter carotid angiography. [2, 24] In the early 2000s, Yoon  
22 et al.[38] and Honda et al.[9] reported the usefulness of magnetic resonance (MR)  
23 angiography to evaluate the development of the external carotid artery tributaries,  
24 including the STA, middle meningeal artery (MMA), and deep temporal artery (DTA)  
25 after direct and/or indirect bypass surgery for MMD. Recent studies using time-of-flight  
26 (TOF) MR angiography or its source image provided insights into the discernable and  
27 sequential roles in direct and/or indirect bypass in MMD. [1, 37] To comprehensively  
28 investigate the clinical and genetic factors associated with the induction of each direct  
29 and indirect surgical collaterals, we retrospectively examined our institutional records  
30 and MR angiography for adult patients undergoing combined direct/indirect bypass for  
31 MMD.

1

## 2 **Materials and Methods**

3 Below are the main methods necessary to comprehend the results. Details were  
4 provided in the online-only supplementary information.

### 5 Study Population

6 This study included all adult MMD patients (>16 years of age at the surgery) who  
7 consented to genetic analysis and underwent repeat MR imaging within 3 years after  
8 combined direct/indirect bypass [10, 19] between 2005 and 2019 in our hospital. The  
9 diagnosis of MMD was confirmed by the criteria outlined in the Japanese guidelines for  
10 the diagnosis and treatment of MMD. [30] The Houkin MR angiographical  
11 stage/grading system was used to stratify the angiographical stage of MMD (ranging 1  
12 to 4 [most advanced]). [11] Cerebrovascular reactivity to acetazolamide was evaluated  
13 quantitatively as previously reported. [36] According to our surgical protocol, [10, 19]  
14 double-barrel STA-MCA anastomosis combined with EDAMS or EDMAPS was  
15 performed as the standard combined direct and indirect bypass procedure. Basically, we  
16 discontinued antiplatelet(s) before surgery if prescribed, except for 14 operations. Thus,  
17 single antiplatelet agent (cilostazol, aspirin, or clopidogrel) was used in fifteen percent  
18 (14 out of 93) of the surgery. In accordance with an institutional review board-approved  
19 protocol (number14-053), medical records were retrospectively reviewed to gather  
20 demographic information, age at the surgery, symptoms at presentation, comorbid  
21 conditions before surgery, and results of radiographic studies (Please see supplementary  
22 table 1), as well as clinical outcome in terms of global disability and mortality rated by  
23 modified Rankin scale (mRS), and recurrence of ischemic or hemorrhagic stroke when  
24 evaluating the postoperative development of surgical collaterals by MR angiography as  
25 described below.

26 Evaluation of the Postoperative Development of Direct and Indirect Surgical Collaterals  
27 by MR angiography

1 Evaluation of the postoperative development of direct and indirect surgical collaterals  
2 was performed qualitatively and quantitatively using TOF MR angiography and its  
3 source images, respectively, by a previously reported protocol with minor modifications  
4 [36, 37]. In brief, MR angiography at two time points acquired before and 6 to 36  
5 months after surgery were reviewed and compared by neurosurgeons (M. I. and T.S.)  
6 blinded to the results of genetic testing. For qualitative evaluation, [36] postoperative  
7 development of each direct and indirect surgical collaterals were dichotomized into  
8 excellent or not, respectively. Thus, the development of direct surgical collaterals was  
9 evaluated by the development of the STA, while that of indirect surgical collaterals was  
10 evaluated by the development of the MMA and DTA. For quantitative evaluation, we  
11 reviewed MR angiography source images and measured the calibers of the STA, MMA,  
12 and DTA as previously reported.[37] The caliber change ratios (CCRs) of post to  
13 preoperative calibers were calculated for each artery.

#### 14 Genetic Analysis of the *RNF213* founder polymorphism (p.R4810K)

15 Written-informed consent was received for genetic analysis from MMD patients or their  
16 guardians. In accordance with the institutional review board-approved protocol, genetic  
17 analysis was conducted at the Department of Neurosurgery of Hokkaido University by  
18 K.T. and R.T. who were blinded to clinical data. Taqman single nucleotide  
19 polymorphism genotyping assay was employed to determine the allele type for *RNF213*  
20 founder mutation (p.R4810K).

#### 21 Data Analysis

22 Continuous or rank variables were described as the mean or median with standard  
23 deviation or range. Dichotomous or categorical variables were expressed as the ratio or  
24 frequency. “Continuous (age, donor artery diameter) and rank variables (MR  
25 angiographical stage, mRS) were compared between two groups by the unpaired-t test  
26 and Mann-Whitney test, respectively. Dichotomous or categorical variables were  
27 compared by Fisher’s exact test. For multiple comparisons, two-way repeated measures  
28 or ordinary analysis of variance followed by a post-hoc test was used, as appropriate. To  
29 assess the correlation between the excellent development of each surgical collateral and

1 multiple clinical and genetic variables, multivariate logistic regression analysis was  
2 performed using the stepwise forward parameter selection that achieved significance  
3 levels of  $P < 0.1$  in the univariate analysis. All clinical and genetic factors for the  
4 multivariate analysis are listed in the main Tables. The level of significance was set at  $P$   
5  $< 0.05$ . GraphPad Prism (version 9.1.1, San Diego, CA, USA) was used for these  
6 analyses.

7

## 8 **Results**

### 9 Study Population

10 During the study period, 110 adult patients with 160 hemispheres underwent STA-MCA  
11 anastomosis combined with indirect pial synangiosis using vascularized tissue,  
12 including dura mater, temporal muscle, and pericranium. Of these, 48 were excluded  
13 from analysis due to lack of genetic testing, missing follow-up MR imaging within 6 to  
14 36 months after surgery, or the diagnosis of quasi-MMD ( $n=43$ , 2, and 3 patients,  
15 respectively). Consequently, 62 patients (56%) with 93 operated hemispheres (58%)  
16 were included in the analysis: 47 female and 15 male patients with an average age of 42  
17 years. In this study, 79 (84.9%) and five (5.4%) hemispheres underwent double- and  
18 single-barrel STA-MCA anastomosis as the direct bypass procedure, respectively. The  
19 rest of nine hemispheres (9.7%) underwent STA-MCA and ACA anastomosis. In this  
20 series, 99% (92/93 hemispheres) of the direct bypass surgeries were successfully  
21 completed. While, in one hemisphere, intraoperative thrombotic occlusion occurred  
22 repeatedly at the site of anastomosis where white clot formation was observed. This  
23 operation was done by indirect revascularization, since conventional methods were not  
24 effective, including a vessel massage with intravenous heparin administration or a  
25 takedown and re-anastomosis. *RNF213* founder mutation (p.R4810K) was detected in  
26 40 patients (65%) with 59 hemispheres (63%) in this series (Figure 1A). There was no  
27 significant difference in baseline characteristics between *RNF213*-mutant (MT) and  
28 -wild type (WT) groups, except in familial occurrence and a comorbid condition of

1 hypertension (Supplementary Table. 2). A representative patient who was a  
2 heterozygote for the *RNF213* founder mutation is shown in Figure 1B-E.

### 3 Clinical Outcome

4 Overall clinical outcome was favorable in terms of global disability and mortality when  
5 evaluating the development of surgical collaterals by MRA at 319±140 postoperative  
6 days. Thus, fifty-three patients (85.5%) showed favorable outcome (mRS 0-1) and there  
7 was no mortality among the 62 patients with 93 operated hemispheres. In terms of the  
8 recurrence of ischemic or hemorrhagic stroke or TIA, we observed stroke recurrence in  
9 the three operated hemispheres (3.2%) in the three patients (4.8%). There was no  
10 significant correlation between the excellent postoperative development of indirect nor  
11 direct collaterals and stroke recurrence (Table 1 and 2).

### 12 Qualitative and Quantitative MR Angiography Evaluations

13 Of all 93 hemispheres enrolled in this study, excellent development of postoperative  
14 direct and indirect surgical collaterals was observed in 65 (70%), respectively, after the  
15 combined bypass with a mean follow-up period of 319±140 days by qualitative  
16 evaluation. In terms of the relationship of the postoperative development between direct  
17 and indirect bypass, dual/equal development was most frequently observed (62% of the  
18 operated hemisphere). Thus, postoperative direct- (STA) or indirect- (MMA and/or  
19 DTA) dominant development was observed in 44 and 14 hemispheres, respectively,  
20 when evaluated in the above-mentioned follow-up period. By quantitative MR  
21 angiography evaluation of all 93 hemispheres, a significant increase was observed in the  
22 caliber of the STA after surgery (pre: 1.8±0.35 mm; post: 2.5±0.65 mm, P<0.0001). The  
23 caliber of the MMA and DTA also significantly increased (pre: 1.6±0.44 mm; post:  
24 1.8±0.50 mm, P<0.0001 in MMA; pre: 0.98±0.33 mm; post: 1.6±0.60 mm, P<0.0001,  
25 respectively). The CCR of post to preoperative-calibers for the STA was significantly  
26 higher (1.5±0.42 vs 1.0±0.28, P<0.0001) in the excellent direct bypass development  
27 group than in the non-excellent group. The CCRs for the DTA (2.0±0.89 vs 1.2±0.53,  
28 P<0.0001) and MMA (1.3±0.31 vs 1.0±0.29, P=0.042) were also significantly higher in  
29 the excellent indirect bypass development group.

1 We further analyzed the association between direct or indirect bypass  
2 development and *RNF213* founder polymorphism (p.R4810K). Of note, excellent  
3 indirect bypass development was observed more frequently in the *RNF213*-MT group  
4 (78%, 46/59 hemispheres) than in the *RNF213*-WT group (56%, 19/34 hemispheres),  
5 with a significant difference ( $P = 0.035$ ) (Figure 2A). Excellent direct bypass  
6 development was observed in 40/59 hemispheres (68%) and 24/34 hemispheres (71%)  
7 of the *RNF213*-MT and -WT groups, respectively, with no significant difference ( $P =$   
8  $0.82$ ). Multiple comparisons of the CCRs demonstrated a significant difference in the  
9 DTA, but not in the STA or MMA, between the two groups (Figure 2B). Thus, the CCR  
10 for the DTA was significantly higher in the *RNF213*-MT group ( $1.9 \pm 1.0$ ) than in the  
11 *RNF213*-WT group ( $1.4 \pm 0.52$ ,  $P=0.0007$ ).

#### 12 Factors Correlated with Excellent Development of Indirect and Direct Collaterals After 13 Combined Bypass

14 To identify clinical and genetic factors that may underlie excellent revascularization  
15 after combined bypass in adult MMD, we examined which factors correlated with the  
16 excellent development of indirect and direct collaterals (Table 1 and 2). Multivariate  
17 logistic regression analysis for excellent indirect bypass development revealed a  
18 significant positive correlation with *RNF213* founder mutation (adjusted odds ratio  
19 (OR), 4.0), advanced MR angiographic stage (adjusted OR, 13 in stage 3; 9.5 in stage 4),  
20 and preoperative caliber of the MMA (adjusted OR, 6.8), whereas a significant negative  
21 correlation was noted with excellent direct bypass development (adjusted OR, 0.17). On  
22 the other hand, no significant correlation was observed between excellent direct bypass  
23 development and *RNF213* founder mutation. Multivariate logistic regression analysis  
24 for excellent direct bypass development revealed a significant negative correlation with  
25 excellent indirect bypass development (adjusted OR, 0.23) and the comorbid condition  
26 of dyslipidemia (adjusted OR, 0.27). Please see supplementary figure 1 and 2  
27 supporting these results.

28

#### 29 Discussion

1 To our knowledge, this is the first study to demonstrate that the *RNF213* gene  
2 polymorphism (p.R4810K) plays a role in the postoperative development of indirect,  
3 but not direct surgical collaterals after direct STA-MCA anastomosis combined with  
4 indirect pial synangiosis for adult patients with MMD. We were able to document this  
5 relationship by qualitative and quantitative evaluation of repeated TOF MR  
6 angiography during the short to mid-term follow-up period (6 to 36 months after  
7 surgery). Growing number of studies demonstrated that indirect bypass for adult MMD  
8 is less effective in terms of angiographical outcome (postoperative development of  
9 indirect surgical collateral) compared to pediatric or young adult patients. Thus, the  
10 successful indirect bypass development were observed in 44-47% of adult MMD  
11 patients treated with combined direct and indirect bypass [5, 28] or indirect bypass.[21]  
12 Consistent with these past research, our study showed that only 56% of adult MMD  
13 showed excellent indirect bypass development in adult patients without  
14 *RNF213*-founder polymorphism (*RNF213*-WT group, Please see Figure 2A). On the  
15 other hand, most (78%) of patients with *RNF213*-founder polymorphism (*RNF213*-WT  
16 group) demonstrated excellent indirect bypass development. Based on these  
17 observations, preoperative genetic analysis for the *RNF213* founder mutation might be  
18 useful for the clinical management of adult MMD patients, especially when making a  
19 decision whether adding indirect bypass on direct bypass procedure for adult MMD.

20 To further determine key factors responsible for indirect and direct bypass  
21 development, respectively, we focused on significant clinical and genetic factors  
22 correlated with the excellent postoperative development of surgical collaterals by  
23 multivariate logistic regression analyses. We identified a panel of excellent  
24 revascularization-related factors for each indirect and direct bypass development after  
25 combined bypass for adult MMD (main Tables). Of note, 1) p.R4810K variant, 2)  
26 preoperative advanced MR angiographical stage, and 3) preoperative larger caliber of  
27 the MMA were positively, and 4) postoperative excellent direct bypass development  
28 was negatively correlated with excellent indirect bypass development. This is partly  
29 current knowledge. Thus, advanced angiographical stage, preoperative trans-dural  
30 collateral vessels (i.e., MMA), and heterozygous p.R4810K variant are known  
31 radiographic and genetic biomarkers of the increased capacity of postoperative surgical

1 collateral production. [8, 32] In addition to the current knowledge, our study suggests  
2 significant correlation between p.R4810K and excellent indirect, but not direct bypass  
3 development after combined bypass, although its underlying mechanism is unclear  
4 based on our study, which is briefly discussed below. Thus, it remains unclear how  
5 p.R4810K plays a pathological role in MMD (i.e., why earlier disease onset, higher  
6 disease severity, [16, 27] and prolonged/delayed cerebral hyperperfusion after  
7 STA-MCA anastomosis [34] occur more frequently in MMD with the *RNF213* founder  
8 mutation?). Earlier experimental studies reported that cellular gene expression analysis  
9 of *RNF213* in adult human tissues revealed markedly high expression in immune tissues  
10 such as the spleen and leukocytes.[14, 25] Genome-wide plasma/serum microRNA  
11 profiling [6, 13, 35] revealed a panel of significant MMD-related plasma/serum  
12 microRNAs whose target genes were involved in inflammatory or angiogenesis-related  
13 molecular pathways. Bidirectional major pathways that are influential in the  
14 inflammatory response potentially causing collateral formation in MMD are 1) the  
15 anti-inflammatory cytokine pathway and 2) proinflammatory cytokine pathway  
16 activating *RNF213*. Fujimura et al. (2018) recently showed increased serum production  
17 of soluble CD163 and CXCL5 in MMD patients, suggesting the involvement of  
18 intrinsic M2 macrophage-related immune reactions.[7] The immune responses  
19 associated with angiogenesis are promoted by M2 macrophages and angiogenic  
20 mediators are activated through these anti-inflammatory cytokines.[25] Ohkubo et al.  
21 (2015) reported that pro-inflammatory cytokines activated transcription of *RNF213* both  
22 *in vitro* and *in vivo*. p.R4810K variant was more likely linked to the functional  
23 deficiency of the *RNF213* gene based on markedly high matrix metalloproteinase  
24 production upon experimental silencing of *RNF213*. [29] Bang et al. (2016) reported a  
25 marked increase in the blood caveolin-1 level in *RNF213* founder mutation carriers.[3]  
26 As caveolin-1 negatively regulates proliferation of endothelial cells, but positively  
27 regulates endothelial angiogenic function such as tube formation,[22] the increased  
28 caveolin-1 levels may accelerate angiogenesis in MMD patients. *In vivo* experimental  
29 study demonstrated increased angiogenesis in mice lacking *RNF213* after chronic  
30 hind-limb ischemia, [12] suggesting a role of *RNF213* abnormality in the development  
31 of pathological vascular networks in chronic ischemia. Taken together, our observation  
32 of marked angiogenesis represented by excellent indirect bypass development in adult

1 MMD patients with P.R4810K variant can be explained bidirectionally by the  
2 loss-of-function (i.e., marked angiogenesis by lacking *RNF213* gene function) and  
3 gain-of-function (i.e., marked angiogenesis through *RNF213* mutation) mechanisms of  
4 the *RNF213* gene, which is the next question to be addressed.

5 Another novel finding demonstrated in this study is that the comorbid  
6 condition of dyslipidemia was negatively correlated with excellent direct bypass  
7 development. In this study, all the thirteen patients with dyslipidemia in this series were  
8 treated with statin and had well-controlled preoperative blood LDL level before surgery.  
9 There was no significant difference in the preoperative blood LDL level between  
10 dyslipidemia and non-dyslipidemia group ( $125.5 \pm 32.8$  mg/dl and  $122.6 \pm 27.3$  mg/dl,  
11  $P=0.73$ , unpaired t-test). Recently, Church and Steinberg et al. reported an association  
12 between hyperlipidemia and radiological progression of unilateral type to bilateral type  
13 in MMD, with possible explanations including synergistic effects of increased lipids in  
14 the underlying moyamoya vasculopathy and the inadvertent inclusion of cerebral  
15 atherosclerotic disease in the study population.[4] One possible explanation for our  
16 finding may also be the inadvertent involvement of atherosclerosis in our MMD patients,  
17 which leads to a poorer condition of both the donor and recipient arterial wall, resulting  
18 in poor long-term patency. We should further validate this issue in a larger cohort with  
19 optimal stratification by the different (well- or poorly-controlled blood LDL level).

## 20 Limitation

21 Our study is limited by the following several points. First, our study did not include  
22 pediatric subgroup of MMD. As we previously reported that almost all (95%) pediatric  
23 MMD exhibited effective indirect revascularization after combined bypass,[36] we only  
24 investigated adult MMD in this study. Second, catheter angiography follow-up was not  
25 available in the most bypass surgeries in this study, although measurement of vessel  
26 calibers by catheter angiography is optimal. Last, consistent hemodynamic evaluations  
27 were not available for all patients using single-photon emission computed tomography  
28 or positron emission tomography. We do not consider these limitations to affect the  
29 interpretation of the results, but further studies are warranted.

1

## 2 **Conclusions**

3 We found that the excellent development of postoperative indirect pial synangiosis after  
4 combined direct and indirect bypass occurs more frequently in adult MMD patients with  
5 the *RNF213* founder mutation (p.R4810K) allele. This confirms a novel clinical role of  
6 the *RNF213* founder polymorphism in the marked angiogenesis via indirect pial  
7 synangiosis in adult patients with MMD, and suggests the utility of preoperative genetic  
8 analysis for *RNF213* polymorphism in MMD.

9

## 10 **References**

- 11 1. Amin-Hanjani S, Singh A, Rifai H, Thulborn KR, Alaraj A, Aletich V, Charbel  
12 FT (2013) Combined direct and indirect bypass for moyamoya: Quantitative  
13 assessment of direct bypass flow over time. *Neurosurgery* 73:962–968
- 14 2. Bang JS, Kwon OK, Kim JE, Kang HS, Park H, Cho SY, Oh CW (2012)  
15 Quantitative angiographic comparison with the OSIRIS program between the  
16 direct and indirect revascularization modalities in adult moyamoya disease.  
17 *Neurosurgery* 70:625–633
- 18 3. Bang OY, Chung JW, Kim SJ, Oh MJ, Kim SY, Cho YH, Cha J, Yeon JY, Kim  
19 KH, Kim GM, Chung CS, Lee KH, Ki CS, Jeon P, Kim JS, Hong SC, Moon GJ  
20 (2016) Caveolin-1, Ring finger protein 213, and endothelial function in  
21 Moyamoya disease. *Int J Stroke* 11:999–1008
- 22 4. Church EW, Bell-Stephens TE, Bigder MG, Gummidipundi S, Han SS, Steinberg  
23 GK (2020) Clinical course of unilateral moyamoya disease. *Neurosurgery*  
24 87:1262–1268
- 25 5. Czabanka M, Vajkoczy P, Schmiedek P, Horn P (2009) Age-dependent  
26 revascularization patterns in the treatment of moyamoya disease in a European  
27 patient population. *Neurosurg Focus* 26:1–6

- 1 6. Dai D, Lu Q, Huang Q, Yang P, Hong B, Xu Y, Zhao W, Liu J, Li Q (2014)  
2 Serum miRNA Signature in Moyamoya Disease. *PLoS One* 9:e102382
- 3 7. Fujimura M, Fujimura T, Kakizaki A, Sato-Maeda M, Niizuma K, Tomata Y,  
4 Aiba S, Tominaga T (2018) Increased serum production of soluble CD163 and  
5 CXCL5 in patients with moyamoya disease: Involvement of intrinsic immune  
6 reaction in its pathogenesis. *Brain Res* 1679:39–44
- 7 8. Ge P, Ye X, Liu X, Deng X, Wang J, Wang R, Zhang Y, Zhang D, Zhang Q,  
8 Zhao J (2019) Association between p.R4810K Variant and Postoperative  
9 Collateral Formation in Patients with Moyamoya Disease. *Cerebrovasc Dis*  
10 48:77–84
- 11 9. Honda M, Kitagawa N, Tsutsumi K, Morikawa M, Nagata I, Kaminogo M  
12 (2005) Magnetic resonance angiography evaluation of external carotid artery  
13 tributaries in moyamoya disease. *Surg Neurol* 64:325–330
- 14 10. Houkin K, Kamiyama H, Takahashi A, Kuroda S, Abe H (1997) Combined  
15 revascularization surgery for childhood moyamoya disease: STA-MCA and  
16 encephalo-duro-arterio-myo-synangiosis. *Child's Nerv Syst* 13:24–29
- 17 11. Houkin K, Nakayama N, Kuroda S, Nonaka T, Shonai T, Yoshimoto T (2005)  
18 Novel magnetic resonance angiography stage grading for moyamoya disease.  
19 *Cerebrovasc Dis* 20:347–54
- 20 12. Ito A, Fujimura M, Niizuma K, Kanoke A, Sakata H, Morita-Fujimura Y,  
21 Kikuchi A, Kure S, Tominaga T (2015) Enhanced post-ischemic angiogenesis in  
22 mice lacking RNF213; a susceptibility gene for moyamoya disease. *Brain Res*  
23 1594:310–20
- 24 13. Ito M, Uchino H (2020) Detection and quantification of microRNAs (miRNAs)  
25 and high-throughput miRNA profiling. In: *Epigenetics Methods*. Elsevier, pp  
26 479–493
- 27 14. Kamada F, Aoki Y, Narisawa A, Abe Y, Komatsuzaki S, Kikuchi A, Kanno J,  
28 Niihori T, Ono M, Ishii N, Owada Y, Fujimura M, Mashimo Y, Suzuki Y, Hata  
29 A, Tsuchiya S, Tominaga T, Matsubara Y, Kure S (2011) A genome-wide

- 1 association study identifies RNF213 as the first Moyamoya disease gene. *J Hum*  
2 *Genet* 56:34–40
- 3 15. Kazumata K, Ito M, Tokairin K, Ito Y, Houkin K, Nakayama N, Kuroda S,  
4 Ishikawa T, Kamiyama H (2014) The frequency of postoperative stroke in  
5 moyamoya disease following combined revascularization: a single-university  
6 series and systematic review. *J Neurosurg* 121:432–440
- 7 16. Kim EH, Yum MS, Ra YS, Park JB, Ahn JS, Kim GH, Goo HW, Ko TS, Yoo  
8 HW (2016) Importance of RNF213 polymorphism on clinical features and  
9 long-term outcome in moyamoya disease. *J Neurosurg* 124:1221–1227
- 10 17. Kuroda S (2021) Overview of Surgical Revascularization and Long-Term  
11 Outcome in Japan. In: *Moyamoya Disease: Current Knowledge and Future*  
12 *Perspectives*. Springer Singapore, pp 215–227
- 13 18. Kuroda S, Houkin K (2008) Moyamoya disease: current concepts and future  
14 perspectives. *Lancet Neurol* 7:1056–1066
- 15 19. Kuroda S, Houkin K, Ishikawa T, Nakayama N, Iwasaki Y (2010) Novel bypass  
16 surgery for moyamoya disease using pericranial flap: Its impacts on cerebral  
17 hemodynamics and long-term outcome. *Neurosurgery* 66:1093–1101
- 18 20. Kuroda S, Nakayama N, Yamamoto S, Kashiwazaki D, Uchino H, Saito H, Hori  
19 E, Akioka N, Kuwayama N, Houkin K (2021) Late (5–20 years) outcomes after  
20 STA-MCA anastomosis and encephalo-duro-myo-arterio-pericranial synangiosis  
21 in patients with moyamoya disease. *J Neurosurg* 134:909–916
- 22 21. Lee SB, Kim DS, Huh PW, Yoo DS, Lee TG, Cho KS (2012) Long-term  
23 follow-up results in 142 adult patients with moyamoya disease according to  
24 management modality. *Acta Neurochir (Wien)* 154:1179–1187
- 25 22. Liu J, Wang XB, Park DS, Lisanti MP (2002) Caveolin-1 expression enhances  
26 endothelial capillary tubule formation. *J Biol Chem* 277:10661–10668
- 27 23. Liu W, Morito D, Takashima S, Mineharu Y, Kobayashi H, Hitomi T, Hashikata  
28 H, Matsuura N, Yamazaki S, Toyoda A, Kikuta K, Takagi Y, Harada KH,  
29 Fujiyama A, Herzig R, Kriscsek B, Zou L, Kim JE, Kitakaze M, Miyamoto S,  
30 Nagata K, Hashimoto N, Koizumi A (2011) Identification of RNF213 as a

- 1 Susceptibility Gene for Moyamoya Disease and Its Possible Role in Vascular  
2 Development. PLoS One 6:e22542
- 3 24. Matsushima T, Inoue T, Suzuki SO, Fujii K, Fukui M, Hasuo K (1992) Surgical  
4 treatment of moyamoya disease in pediatric patients—comparison between the  
5 results of indirect and direct revascularization procedures. Neurosurgery 31:401–  
6 405
- 7 25. Mikami T, Suzuki H, Komatsu K, Mikuni N (2019) Influence of inflammatory  
8 disease on the pathophysiology of moyamoya disease and quasi-moyamoya  
9 disease. Neurol Med Chir (Tokyo) 59:361–370
- 10 26. Miyamoto S, Yoshimoto T, Hashimoto N, Okada Y, Tsuji I, Tominaga T,  
11 Nakagawara J, Takahashi JC (2014) Effects of extracranial-intracranial bypass  
12 for patients with hemorrhagic moyamoya disease: results of the Japan Adult  
13 Moyamoya Trial. Stroke 45:1415–21
- 14 27. Miyatake S, Miyake N, Touho H, Nishimura-Tadaki A, Kondo Y, Okada I,  
15 Tsurusaki Y, Doi H, Sakai H, Saitsu H, Shimojima K, Yamamoto T, Higurashi  
16 M, Kawahara N, Kawauchi H, Nagasaka K, Okamoto N, Mori T, Koyano S,  
17 Kuroiwa Y, Taguri M, Morita S, Matsubara Y, Kure S, Matsumoto N (2012)  
18 Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe  
19 form of moyamoya disease. Neurology 78:803–810
- 20 28. Mizoi K, Kayama T, Yoshimoto T, Nagamine Y (1996) Indirect  
21 revascularization for moyamoya disease: Is there a beneficial effect for adult  
22 patients? Surg Neurol 45:541–548
- 23 29. Ohkubo K, Sakai Y, Inoue H, Akamine S, Ishizaki Y, Matsushita Y, Sanefuji M,  
24 Torisu H, Ihara K, Sardiello M, Hara T (2015) Moyamoya disease susceptibility  
25 gene RNF213 links inflammatory and angiogenic signals in endothelial cells. Sci  
26 Rep 5:13191
- 27 30. Research Committee on the Pathology and Treatment of Spontaneous Occlusion  
28 of the Circle of Willis, Health Labour Sciences Research Grant for Research on  
29 Measures for Infractable Diseases (2012) Guidelines for diagnosis and treatment

- 1 of moyamoya disease (spontaneous occlusion of the circle of Willis). *Neurol*  
2 *medico-chirurgica* 52:245–266
- 3 31. Scott RM, Smith ER (2009) Moyamoya Disease and Moyamoya Syndrome. *N*  
4 *Engl J Med* 360:1226–1237
- 5 32. Storey A, Scott RM, Robertson R, Smith E (2017) Preoperative transdural  
6 collateral vessels in moyamoya as radiographic biomarkers of disease. *J*  
7 *Neurosurg Pediatr* 19:289–295
- 8 33. Suzuki J, Takaku A (1969) Cerebrovascular “moyamoya” disease. Disease  
9 showing abnormal net-like vessels in base of brain. *Arch Neurol* 20:288–299
- 10 34. Tashiro R, Fujimura M, Katsuki M, Nishizawa T, Tomata Y, Niizuma K,  
11 Tominaga T (2020) Prolonged/delayed cerebral hyperperfusion in adult patients  
12 with moyamoya disease with RNF213 gene polymorphism c.14576G>A  
13 (rs112735431) after superficial temporal artery–middle cerebral artery  
14 anastomosis. *J Neurosurg* 1–8
- 15 35. Uchino H, Ito M, Kazumata K, Hama Y, Hamauchi S, Terasaka S, Sasaki H,  
16 Houkin K (2018) Circulating miRNome profiling in Moyamoya  
17 disease-discordant monozygotic twins and endothelial microRNA expression  
18 analysis using iPS cell line. *BMC Med Genomics* 11:72
- 19 36. Uchino H, Kim JH, Fujima N, Kazumata K, Ito M, Nakayama N, Kuroda S,  
20 Houkin K (2017) Synergistic interactions between direct and indirect bypasses in  
21 combined procedures: The significance of indirect bypasses in moyamoya  
22 disease. *Neurosurgery* 80:201–209
- 23 37. Uchino H, Yamamoto S, Kashiwazaki D, Akioka N, Kuwayama N, Noguchi K,  
24 Kuroda S (2021) Using postoperative remodeling of donor arteries on MR  
25 angiography to predict the development of surgical collaterals in moyamoya  
26 disease. *J Neurosurg* 134:1–9
- 27 38. Yoon HK, Shin HJ, Lee M, Byun HS, Na DG, Han BK (2000) MR angiography  
28 of moyamoya disease before and after encephaloduroarteriosynangiosis. *Am J*  
29 *Roentgenol* 174:195–200

30

1

## 2 **Figure legends**

### 3 **Figure 1. Flow chart for inclusion of the study subjects and representative MR** 4 **angiography of a study subject before and after combined direct/indirect bypass**

5 (A) Flow chart shows the breakdown of inclusion and exclusion of the study subjects.  
6 (B-E) MR angiography (MRA) of a 45-year-old female with Moyamoya disease and the  
7 *RNF213* founder polymorphism (G/A genotype) obtained before and 6 months after left  
8 combined direct and indirect bypass. (B, C) Preoperative axial time-of-flight MRA with  
9 maximal intensity projection (MIP) reconstruction (B) and its source image (C)  
10 depicted the left superficial temporal artery (STA, double arrows) and middle  
11 meningeal artery (MMA, dotted arrows), whereas the deep temporal artery (DTA) was  
12 hardly seen in MIP or its source images preoperatively. (D, E) Follow-up MRA  
13 obtained 6 months after left STA-MCA anastomosis combined with  
14 encephalo-duro-myo-arterio-pericranio-synangiosis demonstrated excellent  
15 development of postoperative direct (STA) and indirect (DTA) surgical collaterals. The  
16 caliber of the STA and DTA were markedly increased after surgery (STA: pre: 1.54  
17 mm; post: 1.99 mm, DTA: pre: 0.53 mm; post: 2.34 mm, MMA: pre: 1.18 mm; post:  
18 1.23 mm) as shown in panel (C) and (E).

19

### 20 **Figure 2. Qualitative and quantitative analysis of postoperative direct and indirect** 21 **collateral development using time-of-flight magnetic resonance angiography**

22 (A) Interleaved bar graph showing the results of qualitative analysis of the axial  
23 time-of-flight MR angiography with maximal intensity projection (MIP) reconstruction  
24 before and after combined bypass to evaluate the development of postoperative indirect  
25 and direct collaterals in adult MMD. ns, not significant; \*P <0.05, Fisher's exact test.  
26 (B) Interleaved scatterplot with bars showing the caliber change ratios for the  
27 superficial temporary artery (STA), deep temporal artery (DTA), and middle meningeal  
28 artery (MMA) from quantitative analysis of the source images of MR angiography

- 1 before and after combined bypass in adult MMD. ns, not significant; \*\*\*P <0.001,
- 2 two-way ANOVA followed by Bonferroni multiple comparison.
- 3

**TABLE 1****Correlation of Postoperative Indirect bypass development with Clinical and Genetic Variables**

Variables	<u>Indirect bypass development</u>		Unadjusted	<i>P</i> value	Adjusted	<i>P</i> value
	Excellent (n = 65)	Non-excellent (n = 28)	Odds Ratio (95% CI)		Odds Ratio (95% CI)	
<i>RNF213</i> founder polymorphism, G/A	46/65 (71%)	13/28 (46%)	<u>2.8 (1.1 to 7.1)</u>	<u>0.028</u>	<b><u>4.0 (1.2 to 16)</u></b>	<b><u>0.034</u></b>
Age, y, mean, SD	41 ± 11	43 ± 9.5	0.98 (0.94 to 1.0)	0.46		
Sex, Male	13/65 (20%)	8/28 (29%)	0.63 (0.23 to 1.8)	0.37		
Familial occurrence	23/65 (35%)	7/28 (25%)	1.6 (0.63 to 4.7)	0.33		
Hemisphere, Left	33/65(51%)	12/28 (43%)	1.4 (0.57 to 3.4)	0.48		
Clinical presentation	Ischemia	45/65 (69%)	17/28 (61%)	1.5 (0.57 to 3.7)	0.43	
	Hemorrhage	5/65 (7.7%)	5/28 (18%)	0.38 (0.10 to 1.5)	0.16	
MR angiographical stage	2 (reference)	12/65 (18%)	18/28 (64%)	-	-	-
	3	34/65 (52%)	7/28 (25%)	<u>7.3 (2.5 to 23)</u>	<u>0.0004</u>	<b><u>13 (3.4 to 62)</u></b> <b><u>0.0004</u></b>

	4	19/65 (29%)	3/28 (11%)	<u>9.5 (2.6 to 47)</u>	<u>0.0019</u>	<b><u>9.5 (1.7 to 73)</u></b>	<b><u>0.017</u></b>
PCA involvement		17/65 (26%)	1/28(3.6%)	<u>9.6 (1.8 to 177)</u>	<u>0.033</u>	4.1 (0.48 to 92)	0.25
Co-morbidities	Hypertension	20/65 (31%)	10/28 (36%)	0.80 (0.32 to 2.1)	0.64		
	Diabetes mellitus	4/65 (6.3%)	2/28 (7.1%)	0.85 (0.16 to 6.4)	0.86		
	Dyslipidemia	12/65 (19%)	1/28 (3.6%)	<u>6.1 (1.1 to 114)</u>	<u>0.09</u>	12 (1.3 to 278)	0.052
Decreased cerebrovascular reserve (10% or less)		24/40 (60%)	9/17 (53%)	1.3 (0.42 to 4.2)	0.62		
Direct bypass development, Excellent		40/65 (62%)	25/28 (89%)	<u>0.19 (0.043 to 0.62)</u>	<u>0.013</u>	<b><u>0.17 (0.03 to 0.75)</u></b>	<b><u>0.029</u></b>
Preoperative donor artery diameter mm, mean, SD	STA	1.8 ± 0.36	1.9 ± 0.32	0.83 (0.23 to 3.0)	0.78		
	MMA	1.6 ± 0.45	1.4 ± 0.40	<u>3.9 (1.3 to 14)</u>	<u>0.023</u>	<b><u>6.8 (1.8 to 35)</u></b>	<b><u>0.010</u></b>
	DTA	1.0 ± 0.36	0.95 ± 0.34	1.6 (0.41 to 6.7)	0.50		
	BA	3.0 ± 0.47	3.1 ± 0.61	0.67 (0.27 to 1.6)	0.36		
Clinical outcome	mRS, median	0	0	NA	NA		
	Stroke recurrence	11/65 (16.9%)	1/28 (3.6%)	4.9 (0.87 to 92)	0.14		
Days after bypass for the assessment		305 ± 127	350 ± 167	1.0 (1.0 to 1.0)	0.17		

Abbreviations: RNF213, ring finger protein 213; CI, confidence interval; SD, standard deviation; PCA, posterior cerebral artery; STA, superficial temporal artery; MMA, middle meningeal artery; DTA, deep temporal artery; BA, basilar artery; NA, not applicable




**TABLE 2****Correlation of Postoperative Direct bypass development with Clinical and Genetic Variables**

Variables	<u>Direct bypass development</u>		Unadjusted Odds Ratio (95% CI)	P value	Adjusted Odds Ratio (95% CI)	P value
	Excellent	Non- excellent				
	(n = 65)	(n = 28)				
<i>RNF213</i> founder polymorphism, G/A	41/65 (63%)	18/28 (64%)	0.95 (0.37 to 2.4)	0.91		
Age, y, mean, SD	42 ± 9.9	42 ± 11	1.0 (0.96 to 1.0)	0.93		
Sex, Male	15/65 (23%)	6/28 (21%)	1.1 (0.39 to 3.4)	0.86		
Familial occurrence	21/65 (32%)	9/28 (32%)	1.0 (0.40 to 2.7)	0.99		
Hemisphere, Left	33/65 (51%)	12/28 (43%)	1.4 (0.57 to 3.4)	0.48		
Clinical presentation	Ischemia	42/65 (65%)	20/28 (71%)	0.71 (0.26 to 1.8)	0.52	
	Hemorrhage	7/65 (11%)	3/28 (11%)	1.0 (0.26 to 5.0)	0.99	
MR angiographical stage	2 (reference)	23/65 (35%)	7/28 (25%)	-	-	
	3	28/65 (43%)	13/28 (46%)	0.66 (0.22 to 1.9)	0.44	
	4	14/65 (22%)	8/28 (29%)	0.53 (0.15 to 1.8)	0.31	
PCA involvement		11/65 (17%)	7/28(25%)	0.61 (0.21 to 1.9)	0.37	
Co-morbidities	Hypertension	21/65 (32%)	9/28 (32%)	1.0 (0.40 to 2.7)	0.99	
	Diabetes mellitus	3/65 (4.6%)	3/28 (11%)	0.40 (0.07 to 2.3)	0.29	
	Dyslipidemia	5/65 (7.7%)	8/28 (29%)	<u>0.21 (0.057 to 0.70)</u>	<u>0.012</u>	<b><u>0.27 (0.073 to 0.93)</u></b>

Decreased cerebrovascular reserve (10% or less)		20/39 (51%)	13/18 (72%)	0.40 (0.11 to 1.3)	0.14		
Indirect bypass development, Excellent		40/65 (62%)	25/28 (89%)	<u>0.19 (0.043 to 0.62)</u>	<u>0.013</u>	<b><u>0.23 (0.05 to 0.77)</u></b>	<b><u>0.029</u></b>
Preoperative donor artery diameter mm, mean, SD							
	STA	1.8 ± 0.32	1.9 ± 0.36	1.2 (0.35 to 4.6)	0.75		
	MMA	1.5 ± 0.32	1.6 ± 0.49	1.9 (0.67 to 5.7)	0.24		
	DTA	0.98 ± 0.30	0.98 ± 0.34	1.1 (0.27 to 4.2)	0.94		
	BA	3.1 ± 0.51	3.0 ± 0.52	0.79 (0.33 to 1.9)	0.60		
Clinical outcome							
	mRS, median	0	0	NA	NA		
	Stroke recurrence	7/65 (10.8%)	4/28 (14.3%)	0.72 (0.20 to 3.0)	0.68		
Days after bypass for the assessment		307 ± 105	323 ± 154	1.0 (1.0 to 1.0)	0.61		


Abbreviations: RNF213, ring finger protein 213; CI, confidence interval; SD, standard deviation; PCA, posterior cerebral artery; STA, superficial temporal artery; MMA, middle meningeal artery; DTA, deep temporal artery; BA, basilar artery; NA, not applicable

Main figures




A

## Qualitative Analysis





B

## Quantitative Analysis




Supplementary data


**A** *RNF213* founder polymorphism p.R4810K




**B** MR angiographical grade




**C** Pre-OP MMA diameter



A



B



## Supplementary Table 1

### Baseline clinical and genetic characteristics of the MMD patients in this study

Variables		N = 93 hemispheres
Age, y, mean (range)		41.9 (19 - 67)
Sex, M:F		21:72
Hemisphere, Rt:Lt		48:45
Clinical presentation	Ischemia	62
	Hemorrhage	10
	Others	21
Co-morbidities	Hypertension	30 (32.3%)
	Diabetes mellitus	6 (6.5%)
	Dyslipidemia	13 (14.0%)
	CKD	1 (1.1%)
Familial occurrence		30 (32.2%)
<i>RNF213</i> founder mutation (p.R4810K)	Homozygous, A/A	0
	Heterozygous, G/A	59 (63.4%)
	Wild-type, G/G	34 (36.6%)
MR angiographical stage, median (range)		3 (2-4)
Preoperative donor artery diameter, mm, mean (range)	STA	1.8 (1.2 - 2.7)
	MMA	1.6 (0.53 - 2.8)
	DTA	0.98 (0.37 - 1.8)
	BA	3.1 (1.9 - 4.3)

## Supplementary Table 2

### Comparison of baseline characteristics among MMD patients with or without *RNF213* founder mutation

Variables		<i>RNF213</i> Mutant, N=59	<i>RNF213</i> Wild- type, N=34	Odds Ratio (95% Confidence interval)	Significance
Age, y, mean (SD)		43.2 (9.07)	39.6 (12.4)		0.11
Sex, M:F		15:44	6:28	1.6 (0.55 to 4.7)	0.45
Familial occurrence		26/59 (44.1%)	4/34 (11.8%)	5.9 (1.9 to 17)	<b>0.0013</b>
Co-morbidities	Hypertension	24/59 (40.7%)	6/34 (17.7%)		
	Diabetes mellitus	3/59 (5.08%)	3/34 (8.82%)	3.2 (1.1 to 8.9)	<b>0.024</b>
	Dyslipidemia	8/59 (13.6%)	5/34 (14.7%)	0.55 (0.12 to 2.5)	0.67
	Chronic Kidney Disease	1/59 (1.72%)	0/34 (0%)	0.91 (0.30 to 2.7)	>0.9999
Hemisphere, Rt:Lt		29:30	19:15	Infinity (0.065 to infinity)	>0.9999
Clinical presentation	Ischemia	44	18	0.76 (0.32 to 1.8)	0.67
	Hemorrhage	4	6		0.083
	Others	11	10		
MR angiographical stage, median		3	3		0.36
Preoperative donor artery diameter					
mm, mean (SD)	STA	1.9 (0.37)	1.7 (0.3)		0.36
	MMA	1.6 (0.48)	1.6 (0.38)		
	DTA	0.95 (0.34)	1.0 (0.30)		0.05
	BA	3.0 (0.54)	3.2 (0.44)		0.88

MMD, Moyamoya disease; RNF213, ring finger protein 213; CI, confidence interval; SD, standard deviation; M, male; F, female  
Rt, right; Lt, left; STA, superficial temporal artery; MMA, middle meningeal artery; DTA, deep temporal artery; BA, basilar artery

## Supplementary materials and methods

### Study Population

A consecutive surgical series of patients with MMD or quasi-MMD was reviewed to identify all patients undergoing combined direct/indirect bypass [1, 4] between 2005 and 2019 at our hospital. The diagnosis of MMD was confirmed by the criteria outlined in the Japanese guidelines for the diagnosis and treatment of MMD. [5] In accordance with the guidelines, patients were offered the surgery if they were symptomatic based on a combination of neuropsychological testing, as reported previously,[3] and radiological studies, including MR imaging, TOF MR angiography, or had evidence of hemodynamic compromise by cerebral blood flow (CBF) measurements by [<sup>123</sup>I] N-isopropyl-iodoamphetamine single photon emission tomography, with acetazolamide challenge if safely applicable. Repeat MR imaging and MR angiography after surgery were recommended at 3, 6, and 12 months, and yearly thereafter, but due to patient preference or willingness, it was not always available at all time points. This study included adult MMD patients (>16 years of age at the surgery) who consented to genetic analysis and underwent repeat MR imaging within 3 years after surgery. quasi-MMD was excluded. The Houkin MR angiographical stage/grading system was used to stratify the angiographical stage of MMD (ranging 1 to 4 [most advanced]).[2] Cerebrovascular reactivity (CVR) to acetazolamide was evaluated quantitatively as previously reported.[6] In accordance with an institutional review board-approved protocol (number14-053), medical records were retrospectively reviewed to gather demographic information, age at the surgery, symptoms at presentation, comorbid conditions before surgery, and results of radiographic studies.

### Surgical Procedure

According to our surgical protocol, [1, 4] double-barrel STA to MCA anastomosis combined with EDAMS or EDMAPS was performed as the standard combined direct and indirect bypass procedure. Briefly, after large frontotemporal craniotomy, the dura was opened while preserving the MMA. Both of the parietal and frontal branches of the STA

were anastomosed to the cortical branches of the MCA in an end-to-side manner. The dural flap was inverted and placed on the surface of the brain to increase collateral formation. The temporal muscle was sutured to the edge of the dura. In the EDMAPS procedure, paramedian craniotomy was also performed to improve revascularization in the area of the anterior cerebral artery (ACA). The majority of these patients underwent indirect bypass using the periosteal flap, whereas the remaining patients underwent STA to ACA anastomosis. Basically, we discontinued antiplatelet(s) before surgery if prescribed, except for 14 operations. Thus, single antiplatelet agent (cilostazol, aspirin, or clopidogrel) was used in fifteen percent (14 out of 93) of the surgery.

#### Evaluation of the Postoperative Development of Direct and Indirect Surgical Collaterals by MR angiography

Evaluation of the postoperative development of direct and indirect surgical collaterals was performed qualitatively and quantitatively using TOF MR angiography and its source images, respectively. For qualitative evaluation,[6] postoperative development of each direct and indirect surgical collaterals were dichotomized into excellent or not, respectively. As defined below, the development of direct surgical collaterals was evaluated by the development of the STA, whereas that of indirect surgical collaterals was evaluated by the development of the MMA and DTA. Thus, we reviewed the caliber and course of the STA towards the site of direct anastomosis on TOF MR angiography with maximal intensity projection (MIP) reconstructions after surgery. When we were able to clearly follow the STA towards the anastomotic site with increased caliber after surgery, postoperative STA development was considered excellent. When we were unable to follow the STA to the anastomotic site with its unchanged or reduced caliber, we considered it to be fair or poor. For the indirect surgical collaterals, we compared the calibers of the MMA and DTA on MR angiography after surgery. When the caliber of both arteries increased, we considered the indirect bypass development to be excellent. When the caliber of either artery increased, we considered the indirect bypass development to be fair. In all other cases, it was considered poor. Lastly, the postoperative development of direct surgical collaterals was defined as excellent for the hemispheres with excellent STA development, and that of indirect collaterals was defined as excellent for the hemispheres with excellent or fair MMA and/or DTA development. We also

evaluated the relationship between direct or indirect bypass and postoperative development based on their dominance as follows: direct dominant, indirect dominant, and dual/equal development.

For quantitative evaluation, we reviewed MR angiography source images and measured the calibers of the STA, MMA, and DTA as previously reported.[7] For direct bypass, we compared the caliber of the STA after surgery at the proximal portion of the STA bifurcation into frontal/parietal branches. For indirect bypass, the calibers of the DTA at the most proximal portion and MMA near the foramen spinosum were measured after surgery. The caliber change ratios (CCRs) of post to preoperative calibers were calculated for each artery. The calibers of the basilar artery were also measured before and after surgery as an internal control to validate the reliability of the measurement. The mean caliber of the basilar artery was not significantly different after surgery ( $3.1\pm 0.52$  mm vs.  $3.0\pm 0.50$  mm).

The successful patency of the direct bypass immediately after surgery was further assessed using MR angiography acquired on  $2.1\pm 2.5$  postoperative days. When we were able to clearly follow the STA towards the anastomotic site, the direct bypass was considered patent. When we were unable to follow the STA to the anastomotic site with its reduced caliber, we considered it was not patent. As a result, the rate of successful patency of direct bypass was 93.5% (86/92 hemispheres with completed direct bypass surgery) right after surgery. While, at the timing of follow-up ( $319\pm 140$  postoperative days), it was 96.7% (89/92 hemispheres), indicating immediate postoperative patency was not significantly different between right after surgery and about a year follow-up. Out of the six direct bypasses poorly visualized by MR angiography immediately after surgery, all (6 hemispheres) showed excellent indirect bypass development in the follow-up MRA. Whereas, 58 out of 86 hemispheres (67%) with good direct bypass immediately after surgery showed excellent indirect bypass development. There was no independent relationship between poor direct bypass immediately after surgery and postoperative development of indirect collaterals ( $P=0.17$ , Fisher's exact test). This is probably because dual/equal development was most frequently observed (62% of the operated hemisphere) in this series. Taken together, we could not claim that poor direct bypass immediately after the surgery potentially affect better indirect bypass eventually.

## Genetic Analysis of the *RNF213* founder polymorphism (p.R4810K)

In accordance with the institutional review board-approved protocol, written-informed consent was received for genetic analysis from MMD patients or their guardians. Whole blood samples were collected from the study participants with written informed consent, centrifuged immediately, and blood cell pellets were stored at  $-80^{\circ}\text{C}$  until further analysis at Hokkaido University Hospital Clinical Research and Medical Innovation Center. Genetic analysis was conducted at the Department of Neurosurgery of Hokkaido University by K.T. and R.T. who were blinded to clinical data. Thus, genomic DNA was extracted using the QIASymphony DSP DNA Midi Kit (937255, QIAGEN, Hilden, Germany) from the blood cells. Real-time polymerase chain reaction (PCR) was performed using Light Cycler 96 (Roche, Mannheim, Germany). PCR reaction mixtures were prepared using the Taqman genotyping master mix (4371355, Applied Biosystems, Foster City, CA, USA) and Taqman single nucleotide polymorphism genotyping assay (4351379, Thermo Fisher Scientific, Waltham, MA, USA) to identify *RNF213* founder mutation (p.R4810K). According to the manufacturer's instructions, the thermal cycling conditions were as follows: primary enzyme activation at  $95^{\circ}\text{C}$  for 10 minutes, followed by 40 cycles of denaturation at  $95^{\circ}\text{C}$  for 15 seconds, and annealing and extension at  $60^{\circ}\text{C}$  for 1 minute. After PCR amplification, an endpoint plate read was performed on the real-time PCR instrument to determine the allele type in each sample (p.R4810K, rs112735431, c.14429G>A located at chr 17:80385145 [GRCh38.p12], <https://www.ncbi.nlm.nih.gov/snp/rs112735431>).

## Reference

1. Houkin K, Kamiyama H, Takahashi A, Kuroda S, Abe H (1997) Combined revascularization surgery for childhood moyamoya disease: STA-MCA and encephalo-duro-arterio-myo-synangiosis. *Child's Nerv Syst* 13:24–29
2. Houkin K, Nakayama N, Kuroda S, Nonaka T, Shonai T, Yoshimoto T (2005) Novel magnetic resonance angiography stage grading for moyamoya disease. *Cerebrovasc Dis* 20:347–54

3. Kazumata K, Tha KK, Narita H, Shichinohe H, Ito M, Uchino H, Abumiya T (2016) Investigating Brain Network Characteristics Interrupted by Covert White Matter Injury in Patients with Moyamoya Disease: Insights from Graph Theoretical Analysis. *World Neurosurg* 89:654-665.e2
4. Kuroda S, Houkin K, Ishikawa T, Nakayama N, Iwasaki Y (2010) Novel bypass surgery for moyamoya disease using pericranial flap: Its impacts on cerebral hemodynamics and long-term outcome. *Neurosurgery* 66:1093–1101
5. Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis, Health Labour Sciences Research Grant for Research on Measures for Infractable Diseases (2012) Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). *Neurol medico-chirurgica* 52:245–266
6. Uchino H, Kim JH, Fujima N, Kazumata K, Ito M, Nakayama N, Kuroda S, Houkin K (2017) Synergistic interactions between direct and indirect bypasses in combined procedures: The significance of indirect bypasses in moyamoya disease. *Neurosurgery* 80:201–209
7. Uchino H, Yamamoto S, Kashiwazaki D, Akioka N, Kuwayama N, Noguchi K, Kuroda S (2021) Using postoperative remodeling of donor arteries on MR angiography to predict the development of surgical collaterals in moyamoya disease. *J Neurosurg* 134:1–9

## Legends for supplementary figures

Supplementary figure 1: The independent factors correlated with excellent development of indirect surgical collaterals after combined bypass in adult MMD.

(A-C) Stacked bars indicate significant positive correlations of excellent indirect bypass development with the *RNF213* founder mutation (adjusted odds ratio [OR], 4.0) (A), advanced MR angiographical grade (adjusted OR, 13 in stage 3; 9.5 in stage 4) (B), and preoperative caliber of the middle meningeal artery (MMA, adjusted OR, 6.8) (C). (D) Significant negative correlations were noted between excellent indirect bypass development and excellent direct bypass development (adjusted OR, 0.17). \*P <0.05, \*P <0.001, multivariate logistic regression analysis.

Supplementary figure 2: The independent factors correlated with the excellent development of direct surgical collaterals after combined bypass in adult MMD.

Stacked bars indicate significant negative correlations between excellent direct bypass development and the comorbid condition of dyslipidemia (adjusted OR, 0.27) (A) and excellent indirect bypass development (adjusted OR, 0.23) (B). \*P <0.05, multivariate logistic regression analysis.